| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |



From Cardiovascular Genome Unit*, the Department of Medicine, and the Department of Anesthesiology,
Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts; and the Department of Laboratory Medicine and Pathobiology,
University of Toronto, Toronto, Ontario, Canada
| Abstract |
|---|
|
|
|---|
Global analysis of gene expression has proven to be a fruitful means of examining the overall molecular portrait of a particular event as well as seeking out novel candidate transcripts that may play a role in formulating the phenotype or genotype of interest. By using this strategy, multiple genes and pathways in complex disorders can be visualized simultaneously, allowing for a feasible platform from which to investigate new and interesting genes. Using expressed sequence tag technology, our laboratory has generated a compendium of genes expressed in the human cardiovascular system, with the ultimate goal of assembling the intricacies of development and of disease, particularly the pathways leading to heart failure.3 Through a computer-based in silico strategy, we have been able to identifyin a large scaleboth known and previously unsuspected genetic modulators contributing to the growth of the myocardium from fetal through adult, and from normal to a perturbed hypertrophic phenotype. In contrast a gene-by-gene approach in elucidating the genes and mechanisms involved is time-consuming and cumbersome.
Recently, microarray technology has been used as a means of large-scale screening of vast numbers of genesif not whole genomesthat possess differential expression in two distinct conditions. Although new and exciting developments have arisen in such fields as cancer4 and yeast,5 advances in understanding the complexity of cardiovascular disease,6 specifically DCM, have been limited. One recent study examined gene expression in two failing hearts using oligo-based arrays.7 Although the GeneChip® (Affymetrix, Santa Clara, CA) offers a carefully controlled systematic method of analysis, its current lack of user flexibility in its design hinders novel gene discovery currently available in tissue-specific arrays. Our laboratory has taken advantage of our vast previously acquired resources and has constructed what we believe to be the first ever custom-made cardiovascular-based cDNA microarray, which we term the "CardioChip."8 Its practicality and flexibility has allowed us to conceptualize the molecular events surrounding end-stage heart failure.
| Materials and Methods |
|---|
|
|
|---|
In the process of our large-scale sequencing project, PCR products were generated from human fetal and adult heart, familial hypertrophic cardiomyopathy heart and vascular cDNA libraries, as described previously.9-13
After sequence similarity searching using BLAST14
in the "nr" and "dbest" databases, a nonredundant set of clones was compiled, assigned to individual wells of 96-well microplates (Corning) and purified as described.8
To construct the CardioChip, we took 113 of these microplates containing 10,848 nonredundant PCR products (Table 1)
, spotted them onto CMT-GAPS-II amino-silane-coated glass microarray slides (Corning) using the GMS 417 arrayer (Affymetrix, Santa Clara, CA) and postprocessed the arrays.15
|
Total RNA was extracted from the left ventricular free wall of five nonfailing human adult hearts (rejected as donors because of infection) and seven explanted dilated cardiomyopathic hearts (from patients undergoing transplantation) using Trizol reagent (Life Technologies, Inc., Grand Island, NY), according to the manufacturers protocol. Integrity of the RNA was verified with a 1% agarose-formaldehyde minigel and concentrations were obtained by measuring absorbance at 260 nm. For the labeling process, two types of experiments were performed. To assess intersample variation, 10 µg of each RNA species (ie, 7 DCM and 5 nonfailing hearts for a total of 12 hybridizations) were oligo-dT primed and probe synthesis was performed in the presence of Cy5-dUTP (Amersham, Arlington Heights, IL) at 42°C.7 A parallel labeling with Cy3-dUTP was performed with human universal reference RNA (Stratagene, La Jolla, CA). After purification of the labeled probe by gel exclusion chromatography (ProbeQuant G-50, Amersham), the two probes of interest were mixed (one with Cy3 and one with Cy5), reduced to a volume of 10 µl and combined with 30 µl of hybridization solution [stock solution containing 100 µl of DIG EasyHyb hybridization solution (Roche, Indianapolis, IN), 5 µl of yeast tRNA (10 mg/ml), 5 µl of human COT1 DNA, 5 µl of poly-dA, and 5 µl of salmon sperm DNA (10 mg/ml) as blocking agents]. The probe solution was then hybridized to the arrayed slide at 37°C overnight. The next day, slides were washed first with 1x standard saline citrate to remove the coverslip (Hybri-Slips; Sigma, St. Louis, MO), then three successive washes of 1x standard saline citrate/0.1% sodium dodecyl sulfate for 15 minutes each at 50°C, followed by a rinse with 1x standard saline citrate. The slides were dried in individual 50-ml conical tubes and centrifuged at 500 rpm to remove excess fluid. Scanning of the slides was performed using the GMS 418 scanner (Affymetrix) at 532 nm (Cy3) and 635 nm (Cy5).
To identify interesting clusters of genes showing differential expression, three individual DCM RNA samples were labeled and hybridized against a pool of nonfailing heart tissue RNA; subsequently, the labeling was reversed (ie, the RNA species labeled with Cy3 in the first experiment was labeled with Cy5 in a subsequent experiment). Altogether, six individual reverse-dye-labeling hybridization experiments were performed (three tissues times two experiments each).
Data Processing
Raw scanned images of Cy3 and Cy5 fluorescence were processed using ScanAlyze 2.44 microarray image analysis software (Eisen, MB http://rana.lbl.gov). Local background was subtracted from the fluorescent value of each spot to obtain a net value. Spots whose net fluorescent value did not exceed the mean value obtained from the 192 bacterial-negative control spots were excluded. To account for incomplete hybridization on each spot, we only included in our analysis those spots in which at least 50% of pixels (within the defined area of the spot) displayed fluorescence at least 1.5 times greater than local background in all experiments.
Cluster Analysis
To determine congruence of the DCM and nonfailing heart tissue samples, expression data from the 12 samples were submitted to hierarchical clustering analysis (GeneSpring version 4.1.1; Silicon Genetics, Redwood City, CA). The median ratio for each spot (MRAT; calculated as the ratio of the median fluorescence from each pixel, minus background, in Cy5 to that in Cy3) was entered. Spots that did not meet the background-filtering criteria stated above were omitted. Hybridization results from reverse-dye-labeling were also clustered (Cluster, Eisen, MB http://rana.lbl.gov) using the same criteria.
Verification of Candidate Gene Expression Using Quantitative Real-Time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
To confirm the expression patterns of certain candidate genes, expression of eight transcripts [atrial natriuretic peptide (ANP), elongation initiation factor 1A-Y isoform (EIF1AY), Ca2+/calmodulin kinase kinase (CaCKK), inositol 1,4,5-triphosphate-3-kinase (InosK), inositol 1,4,5-triphosphate receptor (InosTR), cardiac Ca2+ ATPase (CCaATPase), and putative heart-specific expressed sequence tags cnn3870 and ha6788] were analyzed using quantitative real-time RT-PCR (QRT-PCR) in 96-well format (Applied Biosystems, Foster City, CA). For each gene of interest, single QRT-PCR reactions were performed on each individual DCM heart (n = 7) and nonfailing adult heart (n = 5) mRNA samples. As an internal control, primers for GAPDH were also designed and amplified in parallel with the genes of interest. One-step QRT-PCR reactions were performed using 100 ng of total RNA per reaction. Primers were designed online (http://alces.med.umn.edu/rawprimer.html), verified for complementarity (http://www.basic.nwu.edu/biotools/oligocalc.html), and searched against the public database to confirm unique amplification products (http://www.ncbi.nlm.nih.gov). The primer sequences were: 1) ANP forward: 5' GGA TTT CAA GAA TTT GCT GG3', reverse: 5' GCA GAT CGA TCA GAG GAG TC3'; 2) EIF1A forward: 5' CAT CCT TTG TGC CTC GGT TA3', reverse: 5' TGG TTG CCA CTT ATT GTT CG3'; 3) cnn3870 forward: 5' GCC ACT TTG GAA AAG GTG AG3', reverse: 5' CGA CTG GGT TTG GAT GTG AT3'; 4) ha6788 forward: 5' AGA CAA CCT AGT GGC CGT GAC3', reverse: 5' TCC ATA GAT GTT CAC AGC GTT3'; 5) InosTR forward: 5' TTG CCT TCT CTG GGA TTC AG 3', reverse: 5' TTT CCT GGG GCT TAC TGT TG 3'; 6) InosK forward: 5' GCC ACC ATC AGG TTA ATT GG 3', reverse: 5' ACT TTT CCA CGT TGG TCT CG 3'; 7) CaCKK forward: 5' ACC TCC TGG TCG GAG AAG AT 3', reverse: 5' AGA AGA TCT TGC GGG TCT CA 3'; 8) CCaATPase forward: 5' CCT TTT CAT CTG TCG CTG TTG 3', reverse: 5' CGA ACA CCC TTA CAT TTC TGC 3'; 9) GAPDH forward: 5' TGG GTG TGA ACC ATG AGA AG 3', reverse: 5' GTG TCG CTG TTG AAG TCA GA 3'. All reactions were carried in 50-µl volumes containing 1x SYBR Green PCR Master Mix, 0.25 U/µl of Multiscribe Reverse Transcriptase (Applied Biosystems), 0.4 U/µl of RNase inhibitor, and 10 pmol of each forward and reverse primer. Reactions in 96-well format were performed in the Applied Biosystems ABI Prism 7700 Sequence Detection System. The cycling parameters were 30 minutes at 48°C (reverse transcription), followed by PCR: 40 cycles of 30 seconds at 94°C and 1 minute at 60°C.
| Results |
|---|
|
|
|---|
To determine which clones were differentially expressed, processed data were submitted to GeneSpring. The three slides representing the three patient samples were grouped together and treated as replicates; those in which DCM RNA was labeled with Cy3 were pooled into one set, whereas those in which DCM RNA was labeled with Cy5 were pooled into a second set. This generated an average MRAT for each spot (n = 3) in each group. Differential expression was determined as the average MRAT of each spot from three experiments, unless derived from a slide on which DCM was labeled with Cy3; for these, the inverse MRAT was included in the average. A clone was considered to be significantly up- or down-regulated if the average MRAT was significantly different from a ratio of 1.0 (P < 0.05) in at least one of the two sets.
Table 2
lists 145 selected known transcripts from statistical analysis determined to be differentially expressed (of which 111 genes are at a level of at least 1.5-fold) in end-stage heart failure consequent to DCM. Atrial natriuretic peptide (19.15-fold up-regulated) was the most differentially expressed transcript detected in this array. In general, genes encoding numerous sarcomeric and cytoskeletal proteins were consistently up-regulated, including cardiac troponin,
- and ß-cardiac actin, tropomyosin, and ß-myosin heavy chain. An increase in the expression of 40-kd, 70-kd, and 90-kd heat shock proteins were also observed. Several isoforms of collagen were identified as being expressed up-regulated, including
-1 type 1, type XVII, and type XVIII, whereas type XV was down-regulated. Genes encoding proteins regulating transcription and translation were noticeably altered. Elongation initiation factor 1 (eIF-1A) was most prominently up-regulated, as well as elongation factors 1-
and EF-2, but not eIF-2.
|
From hierarchical cluster analysis, the six of seven DCM samples and four of five nonfailing heart samples clustered together (Figure 1)
. Reverse-dye labeling identified two distinct cluster regions that were consistently expressed (Figure 2)
. A cluster of up-regulated genes was enriched in sarcomeric and cytoskeletal proteins, including ß-myosin heavy chain (ß-MyHC), cardiac troponin I, tropomyosin, consistent with the statistical analysis. Another cluster was identified containing predominantly signal transducers (eg, GTP binding protein rho A, ras-like TC25) and energy metabolism modifiers (eg, aldose reductase, electron transfer flavoprotein). Many cardiovascular-enriched expressed sequence tag transcripts were interspersed within both of these clusters.
|
|
Real-time RT-PCR was used to confirm the relative expression patterns of eight transcripts identified by microarray analysis. Threshold values were assigned where the normalized reporter signal
(Rn)-to-noise ratio exceed 1.0 for all genes in the plot. The midpoint of the linear phase of exponential amplification was determined to be the threshold cycle (Ct) for each gene. To determine relative expression levels in each mRNA population, a standard curve was plotted based on expressions of GAPDH in dilutions of nonfailing adult heart RNA (100%, 75%, 50%, 25%, and 12.5% of total stock RNA). For all experimental samples, the amount of product was determined from the standard curve, averaged, and divided by the average amount of GAPDH product to achieve a normalized value. Using a two-tailed Students t-test, significance was calculated by comparing the relative amounts of product between individual DCM and nonfailing adult heart samples. Fold difference was calculated by dividing each sample by the amount of product generated in the mean nonfailing adult heart samples (Figure 3)
. Expression of ANP, cnn3870, EIF1A (up-regulated in DCM), CaCKK, InosK, InosTR CCaATPase, and ha6788 (down-regulated in DCM,) paralleled the results obtained with microarray.
|
| Discussion |
|---|
|
|
|---|
As expected, ANP showed an intense level of up-regulation across the DCM patient samples, confirming at the microarray level its pivotal role as a circulating marker of cardiac muscle stress.16 Indeed, its presence in our analysis lends a degree of credence to the validity of our study. Despite its significant up-regulation versus nonfailing samples, the level of ANP was highly variable among the patients.
In addition, we observed a consistent up-regulation of selected sarcomeric and extracellular matrix proteins (ie, ß-myosin heavy chain,
-actinin,
-cardac actin, troponin I, tropomyosin, collagen, etc). Evidence in knockout mice and human studies has offered insight into the putative role of these proteins in maintaining sarcomeric integrity.1,17-22
Mutations of proteins associated with
-actinin, namely MLP, cardiac
-actin, desmin and titin, have been shown to be present in certain forms of human DCM.23-27
Ambiguities exist in the literature regarding the expression of collagen and other members of the extracellular matrix; nonetheless, regulation of the extracellular matrix is important in the formation of fibrosis and impaired contractile function.28-30
Calcium signaling has recently become an important area of interest in the investigation of heart failure.31
Decrease in calcium cycling genes has been shown to result in reduced contractility in mice whose ß-adrenergic stimulation is blunted leading to decreased phospholamban phosphorylation.32
Ca2+ATPase is key in regulating contractility, and its approximately twofold average down-regulation in our DCM samples lends credence to its involvement. This is supported by a recent study in which the transfer of the Ca2+ATPase gene into the rat myocardium prevents certain features of heart failure.33
The presence of Ca2+/calmodulin-dependent kinase kinase in our analysis, despite showing only
1.1-fold down-regulation, is particularly intriguing, as it is known to phosphorylate phospholamban.34
In addition, inositol 1,4,5-triphosphate receptor (a member of the calcium channel family) that may be responsible for calcium release from intracellular stores,35
was also significantly down-regulated (1.86-fold). Inositol 1,4,5-trisphosphate 3-kinase was recently cloned36
and may be another key component in this regulation (1.86-fold). Our findings suggest that the role of Ca2+ signaling down-regulation may be of crucial significance in the evolution of heart failure and would warrant further investigation.
A number of novel expressed sequence tags were also identified from our study to be differentially regulated. Verification with quantitative real-time RT-PCR confirmed this expression (Figure 3)
. It is an intriguing prospect that these among other transcripts, after full-length sequencing, represent novel cardiac-specific genes encoding proteins that are potentially key to solving the puzzle of the molecular pathophysiology of heart failure. Indeed, our microarray analysis not only serves as a genomic model for a more complete understanding of DCM, but also as a focused target for possible therapeutic interventions specific to the cardiac tissue. Investigations are currently underway to elucidate the function of these candidates.
This report describes the most informative cDNA microarray-based analysis of end-stage heart failure derived from DCM currently available. Although we believe we have effectively demonstrated reproducibility and reliability of our technology (both for the entire array and for a selection of genes located on it), a larger n from our population would enhance the validity of our conclusions. Certainly, there exists no homogeneous heart failure genotype, especially among only seven DCM patients. Nonetheless, we have demonstrated a common expression pattern among our set of samples, from both microarray and QRT-PCR analysis. We are also limited by the genes (both in number and identity) present on this array. Although we are currently unable to spot every gene and gene cluster on our CardioChip, we have tried to draw from a diverse assortment of genes and gene pathways, both known and unknown. It must be emphasized that this investigation is not exhaustive; by no means does it attempt to fully characterize the molecular basis of heart failure. Its intention is to provide a preliminary portrait of global gene expression in complex cardiovascular disease using cDNA microarray and QRT-PCR technology, and to highlight the effectiveness of our ever-evolving platform for gene discovery. With even more patient samples and a CardioChip toward completeness, we will be in a better position to reap the important benefits from this initial work and expand our body of knowledge.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported in part by the Heart and Stroke Foundation of Ontario, the Medical Research Council of Canada, the Canadian Genome Analysis and Technology Program, the National Institutes of Health [grants 5RO1-HL5851603, 5P5O-HL5931603, and 5RO1HL6166102; and a merit award (5R37-HL3561016 to V. J. D.], and the University of Toronto (open fellowship to J. D. B.).
Accepted for publication February 28, 2002.
| References |
|---|
|
|
|---|
Related articles in Am J Pathol:
This article has been cited by other articles:
![]() |
A. Muchir, J. Shan, G. Bonne, S. E. Lehnart, and H. J. Worman Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins Hum. Mol. Genet., January 15, 2009; 18(2): 241 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pluvinet, R. Olivar, J. Krupinski, I. Herrero-Fresneda, A. Luque, J. Torras, J. M. Cruzado, J. M. Grinyo, L. Sumoy, and J. M. Aran CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling Blood, November 1, 2008; 112(9): 3624 - 3637. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Ruppert, T. Meyer, S. Pankuweit, E. Moller, R. C. Funck, W. Grimm, B. Maisch, and German Heart Failure Network Gene expression profiling from endomyocardial biopsy tissue allows distinction between subentities of dilated cardiomyopathy. J. Thorac. Cardiovasc. Surg., August 1, 2008; 136(2): 360 - 369.e1. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Samuel, M. C. Schaub, M. Zaugg, M. Mamas, W. B. Dunn, and B. Swynghedauw Genomics in cardiac metabolism Cardiovasc Res, July 15, 2008; 79(2): 218 - 227. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Haddad, L. J. Saunders, S. D. Crosby, M. Carles, F. del Monte, K. King, M. R. Bristow, F. G. Spinale, T. E. Macgillivray, M. J. Semigran, et al. Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences Physiol Genomics, April 1, 2008; 33(2): 267 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Boudina and E. D. Abel Diabetic Cardiomyopathy Revisited Circulation, June 26, 2007; 115(25): 3213 - 3223. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Foskett, C. White, K.-H. Cheung, and D.-O. D. Mak Inositol Trisphosphate Receptor Ca2+ Release Channels Physiol Rev, April 1, 2007; 87(2): 593 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ojaimi, K. Qanud, T. H. Hintze, and F. A. Recchia Altered expression of a limited number of genes contributes to cardiac decompensation during chronic ventricular tachypacing in dogs Physiol Genomics, March 14, 2007; 29(1): 76 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Ginsburg, D. Seo, and C. Frazier Microarrays Coming of Age in Cardiovascular Medicine: Standards, Predictions, and Biology J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1618 - 1620. [Full Text] [PDF] |
||||
![]() |
M. P. Donahue, D. A. Marchuk, and H. A. Rockman Redefining Heart Failure: The Utility of Genomics J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1289 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hannenhalli, M. E. Putt, J. M. Gilmore, J. Wang, M. S. Parmacek, J. A. Epstein, E. E. Morrisey, K. B. Margulies, and T. P. Cappola Transcriptional Genomics Associates FOX Transcription Factors With Human Heart Failure Circulation, September 19, 2006; 114(12): 1269 - 1276. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF] |
||||
![]() |
E. S. Montana and J. T. Littleton Expression Profiling of a Hypercontraction-induced Myopathy in Drosophila Suggests a Compensatory Cytoskeletal Remodeling Response J. Biol. Chem., March 24, 2006; 281(12): 8100 - 8109. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cunha-Neto, V. J. Dzau, P. D. Allen, D. Stamatiou, L. Benvenutti, M. L. Higuchi, N. S. Koyama, J. S. Silva, J. Kalil, and C.-C. Liew Cardiac Gene Expression Profiling Provides Evidence for Cytokinopathy as a Molecular Mechanism in Chagas' Disease Cardiomyopathy Am. J. Pathol., August 1, 2005; 167(2): 305 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Kittleson, K. M. Minhas, R. A. Irizarry, S. Q. Ye, G. Edness, E. Breton, J. V. Conte, G. Tomaselli, J. G. N. Garcia, and J. M. Hare Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure Physiol Genomics, May 11, 2005; 21(3): 299 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Handley-Goldstone, M. W. Grow, and J. J. Stegeman Cardiovascular Gene Expression Profiles of Dioxin Exposure in Zebrafish Embryos Toxicol. Sci., May 1, 2005; 85(1): 683 - 693. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Volkova, R. Garg, S. Dick, and K. R. Boheler Aging-associated changes in cardiac gene expression Cardiovasc Res, May 1, 2005; 66(2): 194 - 204. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sanoudou, E. Vafiadaki, D. A. Arvanitis, E. Kranias, and A. Kontrogianni-Konstantopoulos Array lessons from the heart: focus on the genome and transcriptome of cardiomyopathies Physiol Genomics, April 14, 2005; 21(2): 131 - 143. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Steenman, G. Lamirault, N. Le Meur, M. Le Cunff, D. Escande, and J. J. Leger Distinct molecular portraits of human failing hearts identified by dedicated cDNA microarrays Eur J Heart Fail, March 2, 2005; 7(2): 157 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wellner, R. Dechend, J.-K. Park, E. Shagdarsuren, N. Al-Saadi, T. Kirsch, P. Gratze, W. Schneider, S. Meiners, A. Fiebeler, et al. Cardiac gene expression profile in rats with terminal heart failure and cachexia Physiol Genomics, February 10, 2005; 20(3): 256 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Pillai, H. M. Russell, J. Raman, V. Jeevanandam, and M. P. Gupta Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H486 - H496. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Kittleson, S. Q. Ye, R. A. Irizarry, K. M. Minhas, G. Edness, J. V. Conte, G. Parmigiani, L. W. Miller, Y. Chen, J. L. Hall, et al. Identification of a Gene Expression Profile That Differentiates Between Ischemic and Nonischemic Cardiomyopathy Circulation, November 30, 2004; 110(22): 3444 - 3451. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Gibbons, C. C. Liew, M. O. Goodarzi, J. I. Rotter, W. A. Hsueh, H. M. Siragy, R. Pratt, and V. J. Dzau Genetic Markers: Progress and Potential for Cardiovascular Disease Circulation, June 29, 2004; 109(25_suppl_1): IV-47 - IV-58. [Full Text] [PDF] |
||||
![]() |
E. J. Crampin, M. Halstead, P. Hunter, P. Nielsen, D. Noble, N. Smith, and M. Tawhai Computational physiology and the physiome project Exp Physiol, January 1, 2004; 89(1): 1 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Berdougo, H. Coleman, D. H. Lee, D. Y. R. Stainier, and D. Yelon Mutation of weak atrium/atrial myosin heavy chain disrupts atrial function and influences ventricular morphogenesis in zebrafish Development, December 15, 2003; 130(24): 6121 - 6129. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Blaxall, R. Spang, H. A. Rockman, and W. J. Koch Differential myocardial gene expression in the development and rescue of murine heart failure Physiol Genomics, October 17, 2003; 15(2): 105 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. McGregor and M. J. Dunn Proteomics of heart disease Hum. Mol. Genet., October 15, 2003; 12(90002): R135 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Chen, E. A. Ashley, D. X.F. Deng, A. Tsalenko, A. Deng, R. Tabibiazar, A. Ben-Dor, B. Fenster, E. Yang, J. Y. King, et al. Novel Role for the Potent Endogenous Inotrope Apelin in Human Cardiac Dysfunction Circulation, September 23, 2003; 108(12): 1432 - 1439. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dobbin, J. H. Shih, and R. Simon Questions and Answers on Design of Dual-Label Microarrays for Identifying Differentially Expressed Genes J Natl Cancer Inst, September 17, 2003; 95(18): 1362 - 1369. [Full Text] [PDF] |
||||
![]() |
J. BORLAK and T. THUM Hallmarks of ion channel gene expression in end-stage heart failure FASEB J, September 1, 2003; 17(12): 1592 - 1608. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Grzeskowiak, H. Witt, M. Drungowski, R. Thermann, S. Hennig, A. Perrot, K. J. Osterziel, D. Klingbiel, S. Scheid, R. Spang, et al. Expression profiling of human idiopathic dilated cardiomyopathy Cardiovasc Res, August 1, 2003; 59(2): 400 - 411. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chang, L. Wei, T. Otani, K. A. Youker, M. L. Entman, and R. J. Schwartz Inhibitory Cardiac Transcription Factor, SRF-N, Is Generated by Caspase 3 Cleavage in Human Heart Failure and Attenuated by Ventricular Unloading Circulation, July 29, 2003; 108(4): 407 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Napoli, L O Lerman, V Sica, A Lerman, G Tajana, and F de Nigris Microarray analysis: a novel research tool for cardiovascular scientists and physicians Heart, June 1, 2003; 89(6): 597 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Winslow and M. S. Boguski Genome Informatics: Current Status and Future Prospects Circ. Res., May 16, 2003; 92(9): 953 - 961. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Boheler, M. Volkova, C. Morrell, R. Garg, Y. Zhu, K. Margulies, A.-M. Seymour, and E. G. Lakatta Sex- and age-dependent human transcriptome variability: Implications for chronic heart failure PNAS, March 4, 2003; 100(5): 2754 - 2759. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Steenman, Y.-W. Chen, M. Le Cunff, G. Lamirault, A. Varro, E. Hoffman, and J. J. Leger Transcriptomal analysis of failing and nonfailing human hearts Physiol Genomics, January 15, 2003; 12(2): 97 - 112. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |